October 01

2019

Why is biosimilar adoption slow in the US, and can something be done to boost uptake?

MedCity News

Home
News
Why is biosimilar adoption slow in the US, and can something be done to boost uptake?

Litigation & Dispute Resolution partner Christopher Mikson (Washington DC) was quoted in this article.

Related Capabilities

Practices –

Industries –

Life Sciences

News

October 30

2023

Mayer Brown advises Pernod Ricard on global relationship with The Coca Cola Company
October 10

2023

Mayer Brown advises Cloud Technology Solutions on strategic merger with Appsbroker
October 04

2023

Mayer Brown advises Asolvi on acquisition of Dr. Herwig Computer & Systemberatung GmbH
September 29

2023

Mayer Brown advises The Halifax Group on acquisition of Sodexo’s Worldwide Home Care division
September 22

2023

Mayer Brown advises new client Collabera on its acquisition of digital consultancies Pracedo and Digiterre